Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background There is no proven specific pharmacological treatment for patients with the
acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS …

The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

Background One of the most malignant tumors in men is prostate cancer that is still incurable
due to its heterogenous and progressive natures. Genetic and epigenetic changes play …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …